Cancer Res. 2000 Oct 15;60(20):5887-94.

Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells.

Kurokawa H, Lenferink AE, Simpson JF, Pisacane PI, Sliwkowski MX, Forbes JT, Arteaga CL.

Source

Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA.

Abstract

HER2/neu (erbB-2) overexpression has been causally associated with tamoxifen resistance in human breast cancer cells. Forced expression of HER2 in MCF-7 breast cancer cells resulted in mitogen-activated protein kinase (MAPK) hyperactivity and tamoxifen resistance. Inhibition of HER2 and MAPKs with AG1478 and U0126, respectively, as well as dominant-negative MEK-1/2 constructs restored the inhibitory effect of tamoxifen on estrogen receptor (ER)-mediated transcription and cell proliferation. Both AG1478 and U0126 also restored the tamoxifen-mediated association of ER with nuclear receptor corepressor (N-CoR) in the antiestrogen-resistant MCF-7 cells. Treatment with a combination of tamoxifen and a HER2 kinase inhibitor reduced tumor MAPK activity and markedly prevented growth of HER2-overexpressing MCF-7 xenografts in athymic mice. Thus, blockade of HER2 and MAPK signaling may enhance tamoxifen action and abrogate antiestrogen resistance in human breast cancer.

PMID:: 11059787; [PubMed - indexed for MEDLINE]

Free full text

Publication Types, MeSH Terms, Substances, Grant Support

Publication Types

MeSH Terms

Substances

Grant Support

LinkOut - more resources

Full Text Sources

HighWire Press

Other Literature Sources

COS Scholar Universe

Medical

Molecular Biology Databases

TAMOXIFEN - HSDB

Supplemental Content

Save items

Related citations in PubMed

Review Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer. [Clin Cancer Res. 2001]
Review Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
Kurokawa H, Arteaga CL. Clin Cancer Res. 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s.
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. [J Natl Cancer Inst. 2004]
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R. J Natl Cancer Inst. 2004 Jun 16; 96(12):926-35.
Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. [Cancer Res. 2008]
Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.
Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, Schiff R. Cancer Res. 2008 Feb 1; 68(3):826-33.
Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole. [Cancer Res. 2005]
Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole.
Jelovac D, Sabnis G, Long BJ, Macedo L, Goloubeva OG, Brodie AM. Cancer Res. 2005 Jun 15; 65(12):5380-9.
Review ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. [Clin Cancer Res. 2003]
Review ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms.
Kurokawa H, Arteaga CL. Clin Cancer Res. 2003 Jan; 9(1 Pt 2):511S-5S.

See reviews... See all...

Cited by 33 PubMed Central articles

GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells. [BMC Cancer. 2011]
GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells.
Abrhale T, Brodie A, Sabnis G, Macedo L, Tian C, Yue B, Serrero G. BMC Cancer. 2011 Jun 9; 11:231. Epub 2011 Jun 9.
Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts. [Clin Cancer Res. 2011]
Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts.
Rimawi MF, Wiechmann LS, Wang YC, Huang C, Migliaccio I, Wu MF, Gutierrez C, Hilsenbeck SG, Arpino G, Massarweh S, et al. Clin Cancer Res. 2011 Mar 15; 17(6):1351-61. Epub 2010 Dec 7.
Review The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer. [Curr Opin Pharmacol. 2010]
Review The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer.
McDonnell DP, Wardell SE. Curr Opin Pharmacol. 2010 Dec; 10(6):620-8.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances t...
Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells.
Cancer Res. 2000 Oct 15 ;60(20):5887-94.

PubMed
IkappaBalpha gene therapy in tumor necrosis factor-alpha- and chemotherapy-media...
IkappaBalpha gene therapy in tumor necrosis factor-alpha- and chemotherapy-mediated apoptosis of hepatocellular carcinomas.
Cancer Gene Ther. 2000 Oct ;7(10):1315-23.

PubMed
Exploring new treatment strategies in heart failure.
Exploring new treatment strategies in heart failure.
Blood Press Suppl. 2000 ;1:44-8.

PubMed
Cosmetics. A dermatologist looks to the future: promises and problems.
Cosmetics. A dermatologist looks to the future: promises and problems.
Dermatol Clin. 2000 Oct ;18(4):699-709; x.

PubMed
Influence of mate drinking, hot beverages and diet on esophageal cancer risk in ...
Influence of mate drinking, hot beverages and diet on esophageal cancer risk in South America.
Int J Cancer. 2000 Nov 15 ;88(4):658-64.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: